Syncona Ltd - FTSE 250-listed London-based investment trust focused on healthcare - Data from portfolio firm Freeline Therapeutics Holdings PLC's FLT190 liver-directed gene therapy product is positive. FLT190 "continues to be well tolerated". Previously observed instances of mild myocarditis found not to be associated with enduring long-term sequelae, meaning an effect from previous disease or injury.
Current stock price: 188.00 pence
12-month change: down 27%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Syncona (SYNC)